Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
P41594
UPID:
GRM5_HUMAN
Alternative names:
-
Alternative UPACC:
P41594; Q6J164
Background:
Metabotropic glutamate receptor 5 (mGluR5) is a G-protein coupled receptor that plays a pivotal role in synaptic plasticity and neural network activity. It functions by binding glutamate, which triggers a conformational change leading to signaling through G proteins. This signaling pathway activates a phosphatidylinositol-calcium second messenger system, resulting in a calcium-activated chloride current.
Therapeutic significance:
Understanding the role of Metabotropic glutamate receptor 5 could open doors to potential therapeutic strategies.